From Yahoo Finance: 2025-04-28 11:06:00

Viking Therapeutics stock rose 2.3% after Truist Securities analyst Joon Lee lowered the price target to $75 due to competition in the obesity space. Phase 3 trials for VK2735 could make Viking a key player in weight loss drugs, potentially earning $729 million in 2029. However, it remains a speculative stock.

Analysts forecast less than $2 million in revenue for Viking in 2021, growing to $38 million by 2027. While the potential for profit by 2029 is promising, success hinges on the outcome of phase 3 trials. Consider Viking a speculative investment, and diversify your portfolio to mitigate risk.



Read more at Yahoo Finance: Why Viking Therapeutics Stock Popped Today